Vertex Pharmaceuticals Incorporated
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 71
- Registration Number
- NCT05153317
- Locations
- πΊπΈ
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
πΊπΈUPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
πΊπΈRiley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 86
- Registration Number
- NCT05111145
- Locations
- π¦πΊ
The Prince Charles Hospital, Chermside, Australia
π¦πΊAlfred Hospital, Melbourne, Australia
π¦πΊInstitute for Respiratory Health, Nedlands, Australia
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 597
- Registration Number
- NCT05076149
- Locations
- πΊπΈ
Yale New Haven Hospital, New Haven, Connecticut, United States
πΊπΈCentral Florida Pulmonary Group, PA, Orlando, Florida, United States
πΊπΈTulane Medical Center, New Orleans, Louisiana, United States
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 303
- Registration Number
- NCT05034952
- Locations
- πΊπΈ
Arizona Research Center, Phoenix, Arizona, United States
πΊπΈChesapeake Research Group, Pasadena, Maryland, United States
πΊπΈMidwest Clinical Research Center, Dayton, Ohio, United States
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 435
- Registration Number
- NCT05033080
- Locations
- πΊπΈ
Childrens Hospital University of Missouri Health Sciences Center, Columbia, Missouri, United States
πΊπΈJoe DiMaggio Cystic Fibrosis & Pulmonary Center, Hollywood, Florida, United States
πΊπΈAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 274
- Registration Number
- NCT04977336
- Locations
- πΊπΈ
Shoals Medical Trials Inc., Sheffield, Alabama, United States
πΊπΈArizona Research Center, Phoenix, Arizona, United States
πΊπΈAnaheim Clinical Trials, Anaheim, California, United States
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 82
- Registration Number
- NCT04969224
- Locations
- π§πͺ
Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
π§πͺUniversitair Ziekenhuis Brussel - Campus Jette, Brussels, Belgium
π§πͺUniversitair Ziekenhuis Gent, Gent, Belgium
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
- Conditions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 51
- Registration Number
- NCT04923464
- Locations
- πΊπΈ
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
πΊπΈCentral Florida Pulmonary Group, P.A., Orlando, Florida, United States
πΊπΈNational Jewish Health, Denver, Colorado, United States
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 52
- Registration Number
- NCT04786262
- Locations
- πΊπΈ
Northwestern Organ Transplant Center, Chicago, Illinois, United States
πΊπΈUniversity of Chicago, Chicago, Illinois, United States
πΊπΈHospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation
- Conditions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT04702360